Using Al18F-NOTA-FAPI PET/CT to detect certain cancer types
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
PHASE2; PHASE3 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT05749302
This study is testing a new type of imaging called Al18F-NOTA-FAPI PET/CT to see if it can help find certain cancers that have a specific protein linked to worse outcomes.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences (other) |
| Locations | 1 site (Beijing, Chao Yang) |
| Trial ID | NCT05749302 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of Al18F-NOTA-FAPI PET/CT imaging in patients with malignant tumors that express fibroblast-activated proteins (FAP). It aims to assess the imaging quality and tumor detection capabilities of this novel radiotracer, which targets FAP, a protein associated with poor prognosis in various cancers. The study will include patients with diagnosed or suspected FAP-positive tumors and will evaluate the potential of this imaging technique for diagnosis and treatment assessment. The approach is based on the unique expression of FAP in tumor-associated fibroblasts, making it a promising target for cancer imaging.
Who should consider this trial
Good fit: Ideal candidates are patients with suspected or diagnosed malignant tumors expressing fibroblast-activated proteins.
Not a fit: Patients who are pregnant, breastfeeding, or have medical conditions that may interfere with study compliance will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of cancer diagnosis and treatment monitoring for patients with specific tumor types.
How similar studies have performed: Other studies have shown promising results with similar imaging approaches targeting FAP, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspected or clearly diagnosed Malignant Tumors Expressing Fibroblast-activated Proteins * signed written consent. * Willing and able to cooperate with all projects in this study. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where this trial is running
Beijing, Chao Yang
- National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Chao Yang, China (RECRUITING)
Study contacts
- Study coordinator: Gouzhu Hou, M.D.
- Email: 15611145656@163.com
- Phone: 15611145656
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignancy, malignant tumors expressing fibroblast-activated proteins